There is only one single HER3-directed ADC (U3-1402) that is currently under clinical study, which has demonstrated promising results in patients with HER3-positive metastatic breast cancer and metastatic EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.